Previous Close | 81.66 |
Open | 81.25 |
Bid | 78.74 x 200 |
Ask | 79.01 x 100 |
Day's Range | 78.40 - 81.61 |
52 Week Range | 62.55 - 170.47 |
Volume | |
Avg. Volume | 3,901,646 |
Market Cap | 30.36B |
Beta (5Y Monthly) | 1.66 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -15.35 |
Earnings Date | Oct 31, 2024 - Nov 04, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 123.05 |
Levi & Korsinsky, LLP notifies investors in Moderna, Inc. ("Moderna" or the "Company") (NASDAQ: MRNA) of a class action securities lawsuit.
Over the past year, many Moderna, Inc. ( NASDAQ:MRNA ) insiders sold a significant stake in the company which may have...
New Covid-19 shots are on their way, leaving plenty of time to get them before respiratory illness season this fall. The Food and Drug Administration on Thursday gave Moderna —as well as Pfizer and its partner BioNTech —the green light to roll out their new shots in the coming days, both of which target an offshoot of Omicron known as the KP. The two shots will be available to anyone over 6 months of age, a move that comes as Covid hospitalizations continue to climb and remain higher than they were at this time last year, according to data from the Centers for Disease Control and Prevention.